NCT03523819 - A Study of CS1002 in Subjects with Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions

Solid Tumor, Adult

Interventions

DRUG

CS1002

Dose levels will be escalated following a modified 3+3 dose escalation scheme

DRUG

CS1003

Fixed dose at 200mg in combination with CS1002 on a specified dose level

Trial Locations (10)

St Vincent's hospital, Sydney

Southern Medical Day Care Centre, Wollongong

Border Medical Oncology Research Unit, Albury

Orange Health Service, Orange

Alfred Hospital, Melbourne

Boxhill Hospital, Melbourne

Cabrini Health, Malvern

Ashford Cancer Centre Research, Adelaide

Prince of Wales Hospital, Hong Kong

Queen Mary Hospital, Hong Kong